Indiana University School of Medicine, Indianapolis, 46202, USA.
Drugs Aging. 2010 Aug 1;27(8):677-86. doi: 10.2165/11538260-000000000-00000.
The ADNI (Alzheimer's Disease Neuroimaging Initiative) is a large longitudinal study of patients with probable Alzheimer's disease (AD), patients with mild cognitive impairment (MCI) and healthy elderly controls followed for at least 2-3 years. Many participants in the ADNI are being treated with medications, and these may have beneficial or deleterious effects.
The goal of the study was to characterize baseline medication use in the ADNI.
Diagnosis, demographics, medication status, psychometric data and MRI measures of hippocampal volume and entorhinal cortex thickness were obtained for 818 participants from the ADNI cohort. Total number of medications, Beers list (potentially dangerous) medications and AD treatments were also tabulated. ANOVA and logistic regression were used to assess associations between baseline pharmacotherapy and diagnosis, demographics, and selected clinical and MRI variables.
Of the 818 enrolled ADNI participants, 809 were available for analysis in the present study, including 184 patients with AD, 399 patients with MCI and 226 healthy elderly controls. Significant gender differences in recruitment were observed in the MCI group. The average number of medications per participant was 8 (SD 4) and 22% reported treatment with one or more Beers list medications. For symptomatic treatment of MCI or AD, donepezil and memantine were the most commonly reported drugs. As expected, MCI and AD patients with more severe impairment were more likely to be treated. Men received treatment more frequently than women. Older subjects and those with less education were less likely to receive treatment.
AD and MCI participants from the ADNI cohort were being treated with polypharmacy and many were also taking one or more medications with the potential for adverse effects. Off-label use of cholinesterase inhibitors and/or memantine for MCI was common, with more severely affected patients most likely to receive treatment. Differences in the frequency of symptomatic treatment were also observed as a function of age, years of education, gender and disease severity.
ADNI（阿尔茨海默病神经影像学倡议）是一项针对可能患有阿尔茨海默病（AD）的患者、轻度认知障碍（MCI）患者和健康老年人的大型纵向研究，对他们进行了至少 2-3 年的随访。ADNI 中的许多参与者正在接受药物治疗，这些药物可能具有有益或有害的影响。
本研究旨在描述 ADNI 中的基线用药情况。
从 ADNI 队列中获取了 818 名参与者的诊断、人口统计学、用药情况、心理测量数据以及海马体积和内嗅皮层厚度的 MRI 测量值。还列出了总的用药数量、Beers 清单（潜在危险）药物和 AD 治疗药物。使用方差分析和逻辑回归来评估基线药物治疗与诊断、人口统计学以及选定的临床和 MRI 变量之间的关系。
在纳入 ADNI 的 818 名参与者中，809 名参与者可用于本研究分析，包括 184 名 AD 患者、399 名 MCI 患者和 226 名健康老年人对照。在 MCI 组中观察到招募时存在显著的性别差异。每位参与者的平均用药数量为 8（SD 4），22%的人报告使用一种或多种 Beers 清单药物进行治疗。对于 MCI 或 AD 的症状性治疗，多奈哌齐和盐酸美金刚是最常报告的药物。正如预期的那样，病情更严重的 MCI 和 AD 患者更有可能接受治疗。男性接受治疗的频率高于女性。年龄较大的患者和受教育程度较低的患者不太可能接受治疗。
ADNI 队列中的 AD 和 MCI 参与者正在接受多种药物治疗，许多人还在服用一种或多种具有潜在不良反应的药物。对于 MCI，经常出现使用非专利胆碱酯酶抑制剂和/或盐酸美金刚的现象，病情较重的患者最有可能接受治疗。根据年龄、受教育程度、性别和疾病严重程度的不同，症状性治疗的频率也存在差异。
